Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Subscribe To Our Newsletter & Stay Updated